



Belgian Cancer Registry

## CANCER FACT SHEET 2022

### CORPUS UTERI CANCER

ICD-10 C54



## CONCEPTS AND ABBREVIATIONS

**Absolute numbers (N):** The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.

**Average Annual Percentage Change (AAPC):** The average relative change in incidence risk from one year to the next. For example an AAPC of 1.05 (a 5% increase) applied to a cancer risk of 200/100,000 results in a risk of 210/100,000 one year later ( $=200 \times 1.05$ ) and 255/100,000 over 5 years ( $=200 \times (1.05)^5$ ).

**Crude Rate (CR):** The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).

**ESR2013:** Incidence rates standardised to the 2013 revised European Standard Population (ESP): Standardisation is necessary to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is necessary to evaluate the evolution of the risk of cancer diagnosis over time or among regions.

**Net survival:** Often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc. Net survival may exceed 100%, this occurs when the observed survival probability for patients with the cancer type(s) under study is higher than the one for the matched general population (no excess mortality due to cancer).

**Stage:** Cancers are reported with a stage, labelled with a Roman numeral with IV being the most advanced stage. Stage is based on the T-category (extent of the tumour), the N-category (absence or presence and extent of the regional lymph node metastasis) and the M-category (absence or presence of distant metastasis). Stage is reported as a combination of both clinical and pathological stage with priority given to the pathological stage. Clinical information about distant metastases (cM) will always be taken into account, and in case of neo-adjuvant therapy, priority is given to the clinical stage. If stage is unknown, not applicable or not submitted to the Belgian Cancer Registry, the stage is reported as 'unregistered stage'. Stage is reported according to the TNM 8<sup>th</sup> edition: J.D. Brierley, M.K. Gospodarowicz, Ch. Wittekind. TNM Classification of Malignant Tumours, 8th edition: UICC, 2017.

**95% CI:** 95% Confidence Intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.



1. CANCER INCIDENCE .....	5
1.1. Corpus uteri cancer incidence: by region .....	5
1.1.1. Corpus uteri cancer incidence by region: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2022.....	5
1.2. Corpus uteri cancer incidence: by tumour stage .....	6
1.2.1. Corpus uteri cancer incidence by clinical stage (cStage) and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022.....	6
1.2.2. Corpus uteri cancer incidence by pathological stage (pStage) and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022 .....	6
1.2.3. Corpus uteri cancer incidence by stage and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022.....	7
1.2.4. Corpus uteri cancer incidence by tumour type and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022.....	8
1.2.5. Corpus uteri cancer incidence by tumour type, stage and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022.....	9
2. CANCER INCIDENCE TRENDS .....	10
2.1. Corpus uteri cancer incidence trends: by region.....	10
2.1.1. Corpus uteri cancer incidence trends by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022 .....	10
2.2. Corpus uteri cancer incidence trends: by tumour stage.....	11
2.2.1. Corpus uteri cancer incidence trends by stage: number of new diagnoses, crude and age-standardised incidence rates, 2018-2022, including average annual percentage change from 2004 onwards .....	11
2.3. Corpus uteri cancer incidence trends: by tumour type.....	12
2.3.1. Corpus uteri cancer incidence trends by type: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022 .....	12
2.4. Corpus uteri cancer incidence trends: by age group.....	13
2.4.1. Corpus uteri cancer incidence trends by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022.....	13
3. CANCER PREVALENCE .....	14
3.1. Corpus uteri cancer prevalence: by region.....	14
3.1.1. Corpus uteri cancer prevalence by region: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2022.....	14
4. CANCER SURVIVAL.....	15
4.1. Corpus uteri cancer survival: by region .....	15
4.1.1. Corpus uteri cancer survival by region and age group: number at risk and net survival probabilities, 2018-2022 .....	15
4.2. Corpus uteri cancer survival: by tumour type and tumour stage .....	17
4.2.1. Corpus uteri cancer survival by type and clinical stage (cStage): number at risk and net survival probabilities, 2018-2022 .....	17
4.2.2. Corpus uteri cancer survival by type and pathological stage (pStage): number at risk and net survival probabilities, 2018-2022 .....	19

4.2.3. Corpus uteri cancer survival by type and stage: number at risk and net survival probabilities, 2018-2022	21
5. CANCER SURVIVAL TRENDS.....	23
5.1. Corpus uteri cancer survival trends: by tumour stage.....	23
5.1.1. Corpus uteri cancer survival trends by stage: number at risk and net survival probabilities, 2008-2022 ....	23
5.2. Corpus uteri cancer survival trends: by tumour type and tumour stage.....	25
5.2.1. Corpus uteri cancer survival trends by type and stage: number at risk and net survival probabilities, 2008-2022 .....	25
6. CANCER MORTALITY .....	28
6.1. Corpus uteri cancer mortality: by region .....	28
6.1.1. Corpus uteri cancer mortality* by region: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2021 .....	28
7. CANCER MORTALITY TRENDS.....	29
7.1. Corpus uteri cancer mortality trends: by region.....	29
7.1.1. Corpus uteri cancer mortality* trends by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021 .....	29



## 1. CANCER INCIDENCE



### 1.1. Corpus uteri cancer incidence: by region

1.1.1. *Corpus uteri cancer incidence by region: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2022*

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		All ages
Females																						
<b>Belgium</b>	0	0	0	0	0	1	5	5	25	35	60	111	149	226	248	229	161	88	38	4	1,385	22.2
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[1.3]	[1.3]	[6.6]	[9.5]	[15.5]	[27.8]	[39.6]	[67.9]	[84.0]	[99.1]	[90.3]	[65.3]	[54.8]	[19.5]	[23.6]	(21.0; 23.4)
Brussels	0	0	0	0	0	0	0	0	3	5	10	12	6	16	17	19	7	5	3	0	103	21.2
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[6.7]	[12.4]	[26.8]	[35.6]	[20.2]	[64.3]	[79.7]	[110.2]	[53.7]	[49.7]	[52.0]	[0.0]	[16.6]	(17.0; 25.3)
Flanders	0	0	0	0	0	1	3	4	11	24	33	64	94	140	150	150	110	51	21	2	858	22.9
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[1.4]	[1.9]	[5.1]	[11.6]	[14.6]	[26.9]	[41.9]	[70.8]	[86.4]	[104.9]	[98.2]	[59.9]	[49.3]	[16.6]	[25.4]	(21.4; 24.4)
Wallonia	0	0	0	0	0	0	2	1	11	6	17	35	49	70	81	60	44	32	14	2	424	21.1
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.7]	[0.9]	[9.5]	[5.0]	[13.7]	[27.6]	[40.0]	[63.7]	[80.8]	[84.6]	[82.7]	[81.0]	[66.6]	[31.4]	[22.7]	(19.1; 23.2)

## 1.2. Corpus uteri cancer incidence: by tumour stage

1.2.1. Corpus uteri cancer incidence by clinical stage (cStage) and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

cStage	N[CR]				ESR2013 (95%CI)
	15-54	55-74	75+	All ages	
I	70 [2.4]	482 [34.3]	310 [48.9]	862 [14.7]	13.8 (12.9; 14.7)
II	5 [0.2]	19 [1.4]	28 [4.4]	52 [0.9]	0.8 (0.6; 1.0)
III	4 [0.1]	64 [4.6]	45 [7.1]	113 [1.9]	1.8 (1.5; 2.1)
IV	11 [0.4]	56 [4.0]	44 [6.9]	111 [1.9]	1.8 (1.4; 2.1)
X/NA	41 [1.4]	113 [8.1]	93 [14.7]	247 [4.2]	4.0 (3.5; 4.5)

1.2.2. Corpus uteri cancer incidence by pathological stage (pStage) and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

pStage	N[CR]				ESR2013 (95%CI)
	15-54	55-74	75+	All ages	
I	97 [3.3]	508 [36.2]	299 [47.2]	904 [15.4]	14.7 (13.7; 15.6)
II	4 [0.1]	40 [2.9]	30 [4.7]	74 [1.3]	1.2 (0.9; 1.5)
III	9 [0.3]	89 [6.3]	62 [9.8]	160 [2.7]	2.6 (2.2; 3.0)
IV	8 [0.3]	37 [2.6]	20 [3.2]	65 [1.1]	1.1 (0.8; 1.3)
X/NA	13 [0.4]	60 [4.3]	109 [17.2]	182 [3.1]	2.7 (2.3; 3.1)

1.2.3. Corpus uteri cancer incidence by stage and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

Stage	N[CR]				ESR2013 (95%CI)
	15-54	55-74	75+	All ages	
<b>I</b>	97 [3.3]	511 [36.4]	327 [51.6]	935 [15.9]	15.1 (14.1; 16.1)
<b>II</b>	4 [0.1]	41 [2.9]	37 [5.8]	82 [1.4]	1.3 (1.0; 1.6)
<b>III</b>	9 [0.3]	90 [6.4]	76 [12.0]	175 [3.0]	2.8 (2.4; 3.2)
<b>IV</b>	13 [0.4]	70 [5.0]	48 [7.6]	131 [2.2]	2.1 (1.7; 2.5)
<b>X/NA</b>	8 [0.3]	22 [1.6]	32 [5.0]	62 [1.1]	1.0 (0.7; 1.2)

1.2.4. Corpus uteri cancer incidence by tumour type and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

type	N[CR]				ESR2013 (95%CI)
	15-54	55-74	75+	All ages	
<b>Endometrioid carcinoma</b>	81 [2.8]	563 [40.1]	343 [54.1]	987 [16.8]	15.9 (14.9; 16.9)
<b>Serous carcinoma</b>	7 [0.2]	74 [5.3]	65 [10.3]	146 [2.5]	2.3 (2.0; 2.7)
<b>Other and unspecified</b>	43 [1.5]	97 [6.9]	112 [17.7]	252 [4.3]	4.0 (3.5; 4.5)



1.2.5. Corpus uteri cancer incidence by tumour type, stage and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

type	Stage	N[CR]				ESR2013 (95%CI)
		15-54	55-74	75+	All ages	
<b>Endometrioid carcinoma</b>	I	68 [2.3]	437 [31.1]	250 [39.4]	755 [12.9]	12.2 (11.3; 13.1)
	II	2 [0.1]	33 [2.4]	21 [3.3]	56 [1.0]	0.9 (0.7; 1.1)
	III	5 [0.2]	56 [4.0]	40 [6.3]	101 [1.7]	1.6 (1.3; 1.9)
	IV	4 [0.1]	22 [1.6]	15 [2.4]	41 [0.7]	0.7 (0.5; 0.9)
	X/NA	2 [0.1]	15 [1.1]	17 [2.7]	34 [0.6]	0.5 (0.3; 0.7)
<b>Serous carcinoma</b>	I	3 [0.1]	30 [2.1]	23 [3.6]	56 [1.0]	0.9 (0.7; 1.1)
	II	0 [0.0]	3 [0.2]	5 [0.8]	8 [0.1]	0.1 (0.0; 0.2)
	III	3 [0.1]	16 [1.1]	20 [3.2]	39 [0.7]	0.6 (0.4; 0.8)
	IV	1 [0.0]	24 [1.7]	15 [2.4]	40 [0.7]	0.6 (0.4; 0.8)
	X/NA	0 [0.0]	1 [0.1]	2 [0.3]	3 [0.1]	0.1 (0.0; 0.1)
<b>Other and unspecified</b>	I	26 [0.9]	44 [3.1]	54 [8.5]	124 [2.1]	2.0 (1.6; 2.3)
	II	2 [0.1]	5 [0.4]	11 [1.7]	18 [0.3]	0.3 (0.1; 0.4)
	III	1 [0.0]	18 [1.3]	16 [2.5]	35 [0.6]	0.6 (0.4; 0.7)
	IV	8 [0.3]	24 [1.7]	18 [2.8]	50 [0.9]	0.8 (0.6; 1.0)
	X/NA	6 [0.2]	6 [0.4]	13 [2.1]	25 [0.4]	0.4 (0.2; 0.5)

## 2. CANCER INCIDENCE TRENDS



### 2.1. Corpus uteri cancer incidence trends: by region

2.1.1. *Corpus uteri cancer incidence trends by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022*

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	
Belgium	<b>N</b>	1,431	1,383	1,348	1,393	1,466	1,462	1,419	1,430	1,449	1,391	1,464	1,458	1,445	1,400	1,441	1,347	1,308	1,421	1,385		
	<b>CR</b>	27.0	25.9	25.1	25.8	26.9	26.7	25.7	25.6	25.8	24.6	25.8	25.6	25.2	24.3	24.9	23.2	22.4	24.3	23.6		
	<b>ESR2013</b>	28.1	26.9	26.1	26.6	27.5	27.2	26.0	26.0	26.0	24.4	25.5	25.3	25.0	23.7	24.1	22.3	21.3	22.9	22.2	-1.3 (-1.6; -1.0)	2004-2022
Brussels	<b>N</b>	111	105	102	105	116	122	113	100	80	125	106	109	115	111	122	95	99	133	103		
	<b>CR</b>	21.4	20.1	19.3	19.6	21.4	22.1	20.1	17.3	13.7	21.1	17.8	18.1	18.9	18.2	19.9	15.4	16.0	21.4	16.6		
	<b>ESR2013</b>	23.8	22.6	21.9	22.9	24.4	25.8	23.9	20.5	16.9	25.8	21.5	22.2	23.9	22.7	25.1	18.6	19.6	26.8	21.2	-0.3 (-1.3; 0.8)	2004-2022
Flanders	<b>N</b>	862	831	838	859	911	894	830	859	917	855	881	887	872	837	830	834	799	853	858		
	<b>CR</b>	28.3	27.1	27.2	27.7	29.2	28.4	26.2	26.9	28.5	26.5	27.1	27.2	26.6	25.4	25.1	25.1	23.9	25.4	25.4		
	<b>ESR2013</b>	29.0	27.4	27.6	27.9	29.0	28.2	25.7	26.3	27.8	25.1	25.8	25.9	25.1	23.8	23.0	23.0	21.7	22.7	22.9	-1.5 (-1.8; -1.2)	2004-2022
Wallonia	<b>N</b>	458	447	408	429	439	446	476	471	452	411	477	462	458	452	489	418	410	435	424		
	<b>CR</b>	26.3	25.6	23.2	24.3	24.7	25.0	26.5	26.0	24.8	22.5	26.0	25.1	24.8	24.4	26.4	22.5	22.0	23.3	22.7		
	<b>ESR2013</b>	27.7	27.0	24.6	25.1	25.5	25.5	26.9	26.7	25.3	22.8	25.8	24.9	24.9	23.6	25.6	21.8	20.9	22.1	21.1	-1.2 (-1.6; -0.7)	2004-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

## 2.2. Corpus uteri cancer incidence trends: by tumour stage

2.2.1. Corpus uteri cancer incidence trends by stage: number of new diagnoses, crude and age-standardised incidence rates, 2018-2022, including average annual percentage change from 2004 onwards

Stage		2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period
I	N	983	893	885	975	935		
	CR	17.0	15.4	15.2	16.7	15.9		
	ESR2013	16.6	15.0	14.6	15.9	15.1	0.7 (0.4; 1.1)	2004-2022
							4.1 (3.2; 4.9)	2004-2012
							-1.8 (-2.5; -1.2)	2013-2022
II	N	71	82	64	77	82		
	CR	1.2	1.4	1.1	1.3	1.4		
	ESR2013	1.1	1.3	1.0	1.2	1.3	-2.5 (-3.5; -1.5)	2004-2022
III	N	178	173	162	171	175		
	CR	3.1	3.0	2.8	2.9	3.0		
	ESR2013	3.0	2.8	2.7	2.7	2.8	0.6 (-0.3; 1.5)	2004-2022
IV	N	113	115	123	128	131		
	CR	2.0	2.0	2.1	2.2	2.2		
	ESR2013	1.8	1.9	2.0	2.0	2.1	3.7 (2.7; 4.8)	2004-2022
X/NA	N	96	84	74	70	62		
	CR	1.7	1.4	1.3	1.2	1.1		
	ESR2013	1.5	1.3	1.1	1.0	1.0	-12.0 (-13.1; -11.0)	2004-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

## 2.3. Corpus uteri cancer incidence trends: by tumour type

2.3.1. Corpus uteri cancer incidence trends by type: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

type	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period		
<b>Endometrioid carcinoma</b>	<b>N</b>	883	860	866	904	980	1,031	942	1,002	1,034	980	1,041	1,044	1,020	1,013	1,023	967	957	1,031	987			
	<b>CR</b>	16.6	16.1	16.1	16.7	18.0	18.8	17.0	18.0	18.4	17.3	18.3	18.3	17.8	17.6	17.7	16.7	16.4	17.6	16.8			
	<b>ESR2013</b>	17.4	16.9	16.9	17.4	18.5	19.2	17.4	18.3	18.7	17.3	18.2	18.3	17.8	17.1	17.2	16.1	15.7	16.7	15.9	-0.5 (-0.8; -0.2)	2004-2022	
																					0.6 (0.0; 1.3)	2004-2014	
																						-2.0 (-2.7; -1.2)	2015-2022
<b>Serous carcinoma</b>	<b>N</b>	47	52	53	74	78	98	82	91	93	96	114	109	128	119	147	117	123	143	146			
	<b>CR</b>	0.9	1.0	1.0	1.4	1.4	1.8	1.5	1.6	1.7	1.7	2.0	1.9	2.2	2.1	2.5	2.0	2.1	2.4	2.5			
	<b>ESR2013</b>	0.9	1.0	1.0	1.4	1.4	1.8	1.4	1.6	1.7	1.7	2.0	1.9	2.2	2.0	2.4	1.9	2.0	2.3	2.3	5.6 (4.6; 6.7)	2004-2022	
																						13.2 (8.5; 18.1)	2004-2009
																						2.4 (-2.0; 6.9)	2010-2013
																						3.1 (1.0; 5.2)	2014-2022
<b>Other and unspecified</b>	<b>N</b>	501	471	429	415	408	333	395	337	322	315	309	305	297	268	271	263	228	247	252			
	<b>CR</b>	9.4	8.8	8.0	7.7	7.5	6.1	7.1	6.0	5.7	5.6	5.4	5.3	5.2	4.7	4.7	4.5	3.9	4.2	4.3			
	<b>ESR2013</b>	9.8	9.0	8.2	7.8	7.6	6.1	7.2	6.0	5.7	5.4	5.3	5.1	5.0	4.5	4.5	4.2	3.7	3.9	4.0	-5.1 (-5.6; -4.7)	2004-2022	
																						-6.5 (-7.8; -5.2)	2004-2011
																						-4.2 (-5.0; -3.4)	2012-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

## 2.4. Corpus uteri cancer incidence trends: by age group

2.4.1. Corpus uteri cancer incidence trends by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

Age	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, %	(95%CI)	Period	
<b>15-54</b> <b>N</b>	160	155	158	160	162	156	148	140	122	141	151	157	147	128	127	120	105	119	131				
<b>CR</b>	5.7	5.5	5.6	5.6	5.7	5.4	5.1	4.8	4.2	4.8	5.2	5.4	5.1	4.4	4.4	4.2	3.6	4.1	4.5				
<b>ESR2013</b>	5.9	5.7	5.7	5.7	5.7	5.5	5.1	4.8	4.2	4.8	5.1	5.4	5.0	4.4	4.4	4.2	3.7	4.2	4.6	-2.0	(-2.7; -1.3)	2004-2022	
<b>55-74</b> <b>N</b>	854	804	813	812	820	836	785	806	854	744	772	820	801	775	825	744	720	772	734				
<b>CR</b>	78.0	72.8	73.2	72.7	72.8	73.3	67.9	68.6	71.5	61.4	62.8	65.6	62.8	59.4	62.0	54.9	52.3	55.4	52.3				
<b>ESR2013</b>	78.0	73.1	73.7	73.3	73.6	74.1	69.2	69.9	72.9	62.7	64.3	67.0	64.7	60.7	62.9	55.6	52.8	55.7	52.7	-2.1	(-2.5; -1.8)	2004-2022	
																				-1.4	(-2.0; -0.8)	2004-2015	
																					-3.2	(-4.2; -2.2)	2016-2022
<b>75+</b> <b>N</b>	417	424	377	421	484	470	486	484	473	506	541	481	497	497	489	483	483	530	520				
<b>CR</b>	80.2	79.8	69.2	75.5	85.0	81.3	82.8	81.6	78.8	83.7	88.7	77.9	80.6	81.1	80.0	78.6	77.8	85.6	82.0				
<b>ESR2013</b>	78.8	78.9	68.7	75.2	84.6	80.9	82.6	82.2	78.8	83.6	89.6	78.8	83.3	82.7	81.7	81.3	81.2	87.3	85.3	0.6	(0.1; 1.0)	2004-2022	

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

### 3. CANCER PREVALENCE



#### 3.1. Corpus uteri cancer prevalence: by region

3.1.1. *Corpus uteri cancer prevalence by region: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2022*

Region		Females			
		1-year	5-year	10-year	15-year
Belgium	<b>N</b>	1,310	5,502	9,908	13,458
	<b>CR</b>	22.1	92.7	166.9	227
	<b>ESR2013</b>	20.7	86.3	154.1	207.6
Brussels	<b>N</b>	96	423	748	969
	<b>CR</b>	15.2	66.8	118.2	153.1
	<b>ESR2013</b>	19.3	83.8	147.8	191.9
Flanders	<b>N</b>	812	3,354	6,103	8,364
	<b>CR</b>	23.7	98.0	178.3	244.4
	<b>ESR2013</b>	21.3	87.1	156.6	212.7
Wallonia	<b>N</b>	402	1,725	3,057	4,125
	<b>CR</b>	21.4	91.7	162.5	219.3
	<b>ESR2013</b>	19.7	84.9	149.9	200.8



### 4.1. Corpus uteri cancer survival: by region

#### 4.1.1. Corpus uteri cancer survival by region and age group: number at risk and net survival probabilities, 2018-2022

		Net Survival Probability, 2018-2022			
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
Females					
Belgium	All ages	13,995	91.2% (90.7%; 91.8%)	83.5% (82.7%; 84.3%)	80.9% (79.9%; 81.9%)
	15-54	1,141	96.0% (94.9%; 97.2%)	90.8% (89.1%; 92.6%)	88.5% (86.5%; 90.5%)
	55-74	7,680	94.4% (93.9%; 95.0%)	87.4% (86.5%; 88.2%)	84.3% (83.3%; 85.4%)
	75+	5,005	85.0% (83.8%; 86.2%)	75.6% (73.9%; 77.4%)	73.6% (71.3%; 76.0%)
Brussels	All ages	1,107	90.1% (88.1%; 92.2%)	81.2% (78.2%; 84.2%)	80.4% (76.8%; 84.1%)
	15-54	146	95.3% (91.9%; 98.9%)	90.0% (85.1%; 95.2%)	87.6% (81.9%; 93.6%)
	55-74	559	93.5% (91.3%; 95.7%)	84.6% (81.3%; 88.0%)	80.4% (76.4%; 84.5%)
	75+	387	83.2% (78.8%; 87.8%)	72.7% (66.4%; 79.5%)	77.3% (69.2%; 86.3%)
Flanders	All ages	8,468	91.4% (90.7%; 92.1%)	84.7% (83.7%; 85.8%)	82.8% (81.5%; 84.2%)
	15-54	631	95.8% (94.2%; 97.4%)	90.5% (88.2%; 93.0%)	88.0% (85.3%; 90.8%)
	55-74	4,603	94.8% (94.1%; 95.5%)	88.5% (87.4%; 89.6%)	86.5% (85.2%; 87.8%)
	75+	3,128	85.4% (83.9%; 86.9%)	77.6% (75.5%; 79.9%)	76.0% (73.1%; 79.1%)
Wallonia	All ages	4,420	91.1% (90.2%; 92.1%)	81.8% (80.4%; 83.3%)	77.4% (75.6%; 79.2%)
	15-54	364	96.8% (95.0%; 98.7%)	91.7% (88.7%; 94.7%)	89.6% (86.2%; 93.1%)

Net Survival Probability, 2018-2022					
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
	<b>55-74</b>	2,518	94.0% (93.0%; 95.0%)	86.0% (84.5%; 87.5%)	81.2% (79.4%; 83.1%)
	<b>75+</b>	1,490	84.7% (82.5%; 86.9%)	72.0% (68.9%; 75.3%)	67.6% (63.4%; 72.0%)



## 4.2. Corpus uteri cancer survival: by tumour type and tumour stage

### 4.2.1. Corpus uteri cancer survival by type and clinical stage (cStage): number at risk and net survival probabilities, 2018-2022

type	cStage	Net Survival Probability, 2018-2022					
		N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)
Corpus uteri	All	13,995	91.2% (90.7%; 91.8%)	86.4% (85.7%; 87.1%)	83.5% (82.7%; 84.3%)	82.0% (81.1%; 83.0%)	80.9% (79.9%; 81.9%)
	I	6,068	98.7% (98.1%; 99.2%)	96.9% (96.2%; 97.7%)	95.3% (94.3%; 96.3%)	94.2% (93.0%; 95.5%)	93.4% (91.9%; 94.9%)
	II	414	88.8% (85.3%; 92.5%)	81.4% (76.9%; 86.2%)	77.2% (71.9%; 82.7%)	73.3% (67.4%; 79.7%)	69.4% (62.7%; 76.8%)
	III	881	79.6% (76.7%; 82.5%)	68.6% (65.2%; 72.2%)	59.1% (55.4%; 63.0%)	54.4% (50.4%; 58.7%)	53.0% (48.6%; 57.7%)
	IV	898	45.6% (42.4%; 49.1%)	30.6% (27.6%; 34.0%)	23.6% (20.7%; 26.9%)	21.1% (18.3%; 24.4%)	19.0% (16.1%; 22.4%)
	X/NA	5,745	92.4% (91.6%; 93.3%)	87.1% (86.1%; 88.2%)	84.6% (83.4%; 85.8%)	83.3% (82.0%; 84.7%)	82.3% (80.8%; 83.8%)
Endometrioid carcinoma	All	10,038	96.3% (95.8%; 96.8%)	94.4% (93.8%; 95.1%)	92.9% (92.1%; 93.7%)	92.1% (91.1%; 93.0%)	91.4% (90.3%; 92.6%)
	I	4,902	100.0% (99.5%; 100.4%)	99.8% (99.1%; 100.5%)	99.2% (98.3%; 100.2%)	99.1% (97.9%; 100.3%)	98.4% (96.8%; 100.0%)
	II	267	92.6% (88.7%; 96.6%)	86.7% (81.6%; 92.2%)	83.5% (77.5%; 90.1%)	78.6% (71.6%; 86.4%)	76.3% (68.5%; 85.1%)
	III	508	85.3% (81.9%; 88.8%)	79.0% (74.9%; 83.3%)	72.0% (67.3%; 77.1%)	66.7% (61.5%; 72.4%)	66.5% (60.6%; 72.9%)
	IV	338	53.9% (48.7%; 59.7%)	40.9% (35.7%; 46.8%)	33.8% (28.7%; 39.8%)	31.9% (26.7%; 38.1%)	30.7% (25.3%; 37.2%)
	X/NA	4,023	96.9% (96.2%; 97.7%)	94.8% (93.8%; 95.8%)	93.4% (92.2%; 94.7%)	92.6% (91.2%; 94.0%)	92.1% (90.4%; 93.8%)
Serous carcinoma	All	1,240	81.3% (79.0%; 83.7%)	65.3% (62.4%; 68.3%)	56.6% (53.5%; 59.9%)	51.7% (48.4%; 55.2%)	47.5% (43.9%; 51.3%)
	I	385	96.8% (94.3%; 99.4%)	83.9% (79.5%; 88.5%)	74.6% (69.2%; 80.4%)	69.9% (63.9%; 76.5%)	67.0% (60.2%; 74.6%)
	II	45	N<50	N<50	N<50	N<50	N<50
	III	157	77.3% (70.6%; 84.7%)	57.7% (49.9%; 66.8%)	43.4% (35.3%; 53.4%)	38.3% (30.0%; 49.0%)	31.5% (22.8%; 43.5%)
	IV	205	47.5% (41.0%; 55.0%)	29.3% (23.5%; 36.7%)	22.2% (16.6%; 29.5%)	19.0% (13.7%; 26.5%)	13.5% (8.6%; 21.3%)
	X/NA	448	83.4% (79.6%; 87.3%)	66.5% (61.8%; 71.6%)	59.7% (54.7%; 65.1%)	54.1% (48.9%; 59.8%)	50.8% (45.4%; 56.8%)
Other and unspecified	All	2,734	77.2% (75.5%; 78.9%)	66.7% (64.7%; 68.7%)	61.1% (59.0%; 63.3%)	58.8% (56.6%; 61.1%)	57.2% (54.7%; 59.7%)
	I	782	91.3% (89.0%; 93.7%)	85.3% (82.3%; 88.4%)	80.4% (76.8%; 84.2%)	75.3% (71.1%; 79.8%)	74.2% (69.4%; 79.4%)

Net Survival Probability, 2018-2022							
type	cStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)
	II	102	75.8% (67.2%; 85.6%)	66.7% (56.7%; 78.5%)	64.2% (53.5%; 77.2%)	63.1% (51.4%; 77.3%)	60.0% (46.8%; 76.9%)
	III	216	67.6% (61.4%; 74.5%)	52.2% (45.5%; 60.0%)	39.9% (33.2%; 47.9%)	36.9% (30.2%; 45.2%)	35.8% (28.8%; 44.4%)
	IV	355	36.6% (31.8%; 42.1%)	21.6% (17.6%; 26.6%)	14.8% (11.3%; 19.4%)	12.4% (9.0%; 16.9%)	11.1% (7.9%; 15.7%)
	X/NA	1,283	81.4% (79.1%; 83.8%)	70.3% (67.5%; 73.1%)	65.5% (62.6%; 68.6%)	64.5% (61.3%; 67.8%)	62.6% (59.2%; 66.2%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

4.2.2. Corpus uteri cancer survival by type and pathological stage (pStage): number at risk and net survival probabilities, 2018-2022

type	pStage	Net Survival Probability, 2018-2022					
		N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)
Corpus uteri	All	13,995	91.2% (90.7%; 91.8%)	86.4% (85.7%; 87.1%)	83.5% (82.7%; 84.3%)	82.0% (81.1%; 83.0%)	80.9% (79.9%; 81.9%)
	I	9,231	99.9% (99.6%; 100.2%)	99.0% (98.5%; 99.6%)	98.1% (97.4%; 98.8%)	97.7% (96.8%; 98.5%)	97.3% (96.3%; 98.4%)
	II	693	93.3% (91.1%; 95.7%)	86.8% (83.7%; 90.1%)	83.0% (79.3%; 86.9%)	79.7% (75.5%; 84.3%)	78.5% (73.7%; 83.7%)
	III	1,490	88.8% (87.0%; 90.6%)	77.4% (75.1%; 79.9%)	68.5% (65.7%; 71.3%)	64.4% (61.4%; 67.6%)	60.6% (57.2%; 64.1%)
	IV	508	66.1% (62.0%; 70.5%)	45.6% (41.3%; 50.4%)	38.4% (34.0%; 43.3%)	33.3% (28.9%; 38.3%)	28.9% (24.5%; 34.2%)
	X/NA	2,081	59.8% (57.6%; 62.1%)	46.8% (44.5%; 49.3%)	40.6% (38.1%; 43.2%)	37.6% (35.1%; 40.4%)	35.8% (33.1%; 38.7%)
Endometrioid carcinoma	All	10,038	96.3% (95.8%; 96.8%)	94.4% (93.8%; 95.1%)	92.9% (92.1%; 93.7%)	92.1% (91.1%; 93.0%)	91.4% (90.3%; 92.6%)
	I	7,487	100.7% (100.4%; 101.0%)	101.1% (100.7%; 101.6%)	101.0% (100.3%; 101.7%)	101.2% (100.3%; 102.0%)	101.2% (100.1%; 102.3%)
	II	461	96.9% (94.7%; 99.2%)	93.2% (89.9%; 96.7%)	91.4% (87.4%; 95.6%)	88.5% (83.5%; 93.8%)	88.5% (82.8%; 94.6%)
	III	889	91.8% (89.7%; 93.9%)	87.0% (84.4%; 89.8%)	80.6% (77.4%; 84.0%)	76.7% (73.0%; 80.5%)	72.9% (68.7%; 77.4%)
	IV	147	78.0% (71.2%; 85.4%)	67.4% (59.7%; 76.2%)	61.9% (53.6%; 71.5%)	56.7% (47.9%; 67.2%)	53.1% (43.7%; 64.4%)
	X/NA	1,054	70.5% (67.6%; 73.6%)	57.3% (53.9%; 60.8%)	50.8% (47.2%; 54.7%)	47.0% (43.2%; 51.1%)	44.7% (40.6%; 49.1%)
Serous carcinoma	All	1,240	81.3% (79.0%; 83.7%)	65.3% (62.4%; 68.3%)	56.6% (53.5%; 59.9%)	51.7% (48.4%; 55.2%)	47.5% (43.9%; 51.3%)
	I	493	98.8% (96.9%; 100.7%)	90.3% (86.9%; 93.8%)	84.0% (79.7%; 88.4%)	79.1% (74.1%; 84.3%)	76.1% (70.5%; 82.1%)
	II	75	92.6% (85.6%; 100.2%)	79.5% (69.3%; 91.1%)	67.0% (55.3%; 81.2%)	65.8% (53.4%; 81.0%)	61.0% (47.4%; 78.4%)
	III	260	92.2% (88.4%; 96.1%)	66.6% (60.6%; 73.2%)	52.0% (45.5%; 59.5%)	45.6% (38.8%; 53.6%)	39.7% (32.7%; 48.3%)
	IV	162	67.2% (60.1%; 75.1%)	43.5% (36.1%; 52.4%)	33.1% (26.0%; 42.1%)	23.3% (16.8%; 32.3%)	14.9% (9.4%; 23.7%)
	X/NA	250	41.3% (35.4%; 48.2%)	24.3% (19.1%; 30.8%)	19.1% (14.3%; 25.5%)	17.5% (12.8%; 24.0%)	15.0% (10.3%; 21.9%)
Other and unspecified	All	2,734	77.2% (75.5%; 78.9%)	66.7% (64.7%; 68.7%)	61.1% (59.0%; 63.3%)	58.8% (56.6%; 61.1%)	57.2% (54.7%; 59.7%)
	I	1,259	95.5% (94.0%; 96.9%)	89.9% (87.8%; 92.0%)	86.3% (83.8%; 88.9%)	84.2% (81.4%; 87.2%)	82.6% (79.4%; 86.1%)
	II	157	83.2% (77.0%; 89.9%)	71.6% (64.1%; 80.1%)	66.4% (58.1%; 75.8%)	60.9% (52.1%; 71.2%)	58.0% (48.7%; 69.1%)
	III	341	78.6% (74.0%; 83.4%)	60.7% (55.3%; 66.6%)	49.2% (43.5%; 55.6%)	46.7% (40.7%; 53.5%)	44.0% (37.6%; 51.4%)
	IV	200	56.2% (49.6%; 63.7%)	31.1% (25.1%; 38.5%)	24.9% (19.2%; 32.3%)	23.3% (17.5%; 30.9%)	21.4% (15.6%; 29.4%)

Net Survival Probability, 2018-2022							
type	pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)
	X/NA	779	51.1% (47.5%; 54.9%)	39.8% (36.2%; 43.8%)	33.6% (29.9%; 37.7%)	31.3% (27.5%; 35.5%)	30.3% (26.3%; 34.8%)

4.2.3. Corpus uteri cancer survival by type and stage: number at risk and net survival probabilities, 2018-2022

type	Stage	Net Survival Probability, 2018-2022					
		N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)
<b>Corpus uteri</b>	All	13,995	91.2% (90.7%; 91.8%)	86.4% (85.7%; 87.1%)	83.5% (82.7%; 84.3%)	82.0% (81.1%; 83.0%)	80.9% (79.9%; 81.9%)
	I	9,479	99.3% (99.0%; 99.7%)	98.2% (97.6%; 98.7%)	96.9% (96.2%; 97.7%)	96.5% (95.6%; 97.4%)	96.0% (95.0%; 97.1%)
	II	742	90.2% (87.7%; 92.8%)	83.4% (80.1%; 86.8%)	79.1% (75.3%; 83.0%)	75.9% (71.7%; 80.5%)	75.0% (70.3%; 80.1%)
	III	1,630	84.4% (82.5%; 86.4%)	73.0% (70.6%; 75.5%)	64.5% (61.8%; 67.3%)	60.3% (57.4%; 63.4%)	56.2% (53.0%; 59.7%)
	IV	1,124	51.2% (48.2%; 54.3%)	34.1% (31.3%; 37.2%)	26.8% (24.1%; 29.8%)	23.2% (20.5%; 26.2%)	20.4% (17.7%; 23.5%)
	X/NA	1,028	71.9% (68.9%; 75.0%)	58.9% (55.6%; 62.5%)	54.5% (51.0%; 58.3%)	50.9% (47.2%; 54.9%)	49.4% (45.5%; 53.7%)
<i>Endometrioid carcinoma</i>	All	10,038	96.3% (95.8%; 96.8%)	94.4% (93.8%; 95.1%)	92.9% (92.1%; 93.7%)	92.1% (91.1%; 93.0%)	91.4% (90.3%; 92.6%)
	I	7,662	100.4% (100.0%; 100.7%)	100.4% (99.9%; 100.9%)	100.0% (99.3%; 100.7%)	100.1% (99.2%; 101.0%)	100.1% (99.0%; 101.2%)
	II	491	94.7% (92.2%; 97.4%)	90.0% (86.4%; 93.7%)	86.9% (82.7%; 91.4%)	83.9% (78.9%; 89.3%)	83.9% (78.3%; 90.0%)
	III	961	88.3% (86.0%; 90.6%)	82.4% (79.5%; 85.3%)	76.2% (72.9%; 79.7%)	72.0% (68.3%; 75.9%)	67.9% (63.6%; 72.4%)
	IV	403	58.5% (53.7%; 63.7%)	46.1% (41.2%; 51.5%)	38.8% (33.9%; 44.4%)	35.8% (30.8%; 41.6%)	33.6% (28.4%; 39.8%)
	X/NA	521	81.6% (77.8%; 85.4%)	70.4% (65.9%; 75.2%)	66.3% (61.4%; 71.6%)	61.6% (56.3%; 67.4%)	59.2% (53.5%; 65.6%)
<i>Serous carcinoma</i>	All	1,240	81.3% (79.0%; 83.7%)	65.3% (62.4%; 68.3%)	56.6% (53.5%; 59.9%)	51.7% (48.4%; 55.2%)	47.5% (43.9%; 51.3%)
	I	505	97.9% (95.9%; 99.9%)	89.3% (85.9%; 92.9%)	82.7% (78.4%; 87.2%)	78.0% (73.1%; 83.2%)	75.2% (69.6%; 81.2%)
	II	78	91.7% (84.6%; 99.4%)	77.6% (67.4%; 89.3%)	65.4% (53.8%; 79.5%)	64.2% (52.0%; 79.3%)	59.5% (46.2%; 76.7%)
	III	289	85.1% (80.7%; 89.8%)	61.4% (55.5%; 67.9%)	48.1% (42.0%; 55.2%)	42.4% (36.0%; 49.9%)	36.4% (29.9%; 44.3%)
	IV	270	55.9% (50.2%; 62.4%)	34.5% (29.0%; 41.1%)	25.5% (20.3%; 32.0%)	19.4% (14.6%; 25.9%)	12.9% (8.6%; 19.2%)
	X/NA	98	46.1% (36.7%; 57.8%)	27.3% (19.1%; 39.1%)	24.0% (16.2%; 35.6%)	20.7% (13.3%; 32.0%)	19.1% (11.8%; 30.9%)
<i>Other and unspecified</i>	All	2,734	77.2% (75.5%; 78.9%)	66.7% (64.7%; 68.7%)	61.1% (59.0%; 63.3%)	58.8% (56.6%; 61.1%)	57.2% (54.7%; 59.7%)
	I	1,320	93.9% (92.3%; 95.5%)	88.6% (86.4%; 90.8%)	84.5% (81.9%; 87.1%)	82.5% (79.6%; 85.5%)	80.6% (77.2%; 84.1%)
	II	173	76.5% (69.9%; 83.7%)	67.3% (59.8%; 75.9%)	63.1% (55.0%; 72.4%)	58.6% (49.9%; 68.7%)	56.7% (47.5%; 67.7%)
	III	380	74.2% (69.6%; 79.0%)	58.2% (53.0%; 63.9%)	47.2% (41.8%; 53.3%)	44.3% (38.7%; 50.8%)	41.5% (35.6%; 48.5%)

Net Survival Probability, 2018-2022							
type	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)
	IV	452	41.7% (37.3%; 46.6%)	23.2% (19.5%; 27.6%)	16.6% (13.3%; 20.8%)	14.1% (10.9%; 18.3%)	12.9% (9.7%; 17.1%)
	X/NA	411	65.4% (60.6%; 70.6%)	51.6% (46.5%; 57.3%)	46.5% (41.2%; 52.5%)	44.4% (38.9%; 50.7%)	44.1% (38.3%; 50.8%)

## 5. CANCER SURVIVAL TRENDS



### 5.1. Corpus uteri cancer survival trends: by tumour stage

5.1.1. *Corpus uteri cancer survival trends by stage: number at risk and net survival probabilities, 2008-2022*

Period	Stage	Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
<b>2008-2012</b>	<b>All</b>	7,213	91.6% (90.9%; 92.3%)	83.4% (82.3%; 84.5%)	79.8% (78.5%; 81.1%)
	<b>I</b>	4,533	98.5% (97.9%; 99.1%)	95.6% (94.6%; 96.7%)	93.8% (92.4%; 95.2%)
	<b>II</b>	429	94.4% (91.6%; 97.2%)	83.9% (79.4%; 88.8%)	75.9% (70.1%; 82.1%)
	<b>III</b>	710	83.5% (80.6%; 86.5%)	60.0% (56.1%; 64.2%)	51.6% (47.5%; 56.1%)
	<b>IV</b>	364	52.9% (47.9%; 58.5%)	28.2% (23.6%; 33.6%)	21.4% (17.2%; 26.6%)
	<b>X/NA</b>	1,181	81.0% (78.6%; 83.4%)	67.2% (64.2%; 70.4%)	62.3% (58.7%; 66.1%)
<b>2013-2017</b>	<b>All</b>	7,118	91.4% (90.6%; 92.1%)	83.6% (82.5%; 84.7%)	81.0% (79.7%; 82.3%)
	<b>I</b>	4,819	99.3% (98.8%; 99.8%)	96.7% (95.7%; 97.7%)	95.7% (94.4%; 97.1%)
	<b>II</b>	367	87.5% (83.7%; 91.4%)	77.4% (72.2%; 83.0%)	72.5% (66.3%; 79.2%)
	<b>III</b>	773	83.5% (80.7%; 86.4%)	62.7% (59.0%; 66.7%)	54.2% (50.0%; 58.8%)
	<b>IV</b>	515	52.4% (48.1%; 57.0%)	26.7% (22.9%; 31.0%)	21.5% (17.9%; 25.8%)
	<b>X/NA</b>	650	75.3% (71.7%; 79.0%)	59.9% (55.6%; 64.6%)	54.8% (50.0%; 60.1%)
<b>2018-2022</b>	<b>All</b>	6,879	91.0% (90.3%; 91.8%)	83.4% (82.2%; 84.6%)	80.9% (79.2%; 82.6%)
	<b>I</b>	4,660	99.4% (98.8%; 99.9%)	97.2% (96.1%; 98.3%)	96.4% (94.6%; 98.2%)
	<b>II</b>	375	92.8% (89.6%; 96.2%)	80.5% (75.1%; 86.3%)	78.2% (71.1%; 86.2%)
	<b>III</b>	857	85.3% (82.7%; 88.0%)	66.4% (62.6%; 70.5%)	59.1% (54.1%; 64.6%)

Period	Stage	Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
	<b>IV</b>	609	50.1% (46.2%; 54.4%)	27.1% (23.3%; 31.4%)	18.3% (14.2%; 23.6%)
	<b>X/NA</b>	380	65.8% (60.8%; 71.2%)	44.6% (38.9%; 51.2%)	39.3% (32.7%; 47.2%)



## 5.2. Corpus uteri cancer survival trends: by tumour type and tumour stage

### 5.2.1. Corpus uteri cancer survival trends by type and stage: number at risk and net survival probabilities, 2008-2022

Period	type	Stage	Net Survival Probability			
			N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
<b>2008-2012</b>	Endometrioid carcinoma	<b>All</b>	4,986	96.3% (95.6%; 97.0%)	91.2% (90.1%; 92.4%)	88.4% (87.0%; 89.9%)
		<b>I</b>	3,560	99.7% (99.1%; 100.2%)	98.0% (96.9%; 99.1%)	96.9% (95.4%; 98.4%)
		<b>II</b>	302	98.4% (95.9%; 100.9%)	92.4% (87.7%; 97.4%)	84.9% (78.3%; 92.1%)
		<b>III</b>	406	87.4% (83.9%; 91.0%)	70.1% (65.2%; 75.3%)	61.5% (56.0%; 67.4%)
		<b>IV</b>	139	62.7% (54.9%; 71.6%)	39.9% (32.0%; 49.8%)	30.5% (23.1%; 40.3%)
		<b>X/NA</b>	579	88.8% (85.9%; 91.8%)	76.1% (71.9%; 80.6%)	70.9% (65.7%; 76.5%)
	Serous carcinoma	<b>All</b>	442	83.6% (79.9%; 87.5%)	56.7% (51.7%; 62.1%)	48.9% (43.6%; 54.8%)
		<b>I</b>	171	96.3% (92.5%; 100.3%)	83.1% (76.1%; 90.7%)	79.3% (70.9%; 88.8%)
		<b>II</b>	29	N<50	N<50	N<50
		<b>III</b>	111	80.8% (73.2%; 89.2%)	42.0% (33.1%; 53.3%)	29.8% (21.4%; 41.3%)
		<b>IV</b>	70	64.4% (53.8%; 77.1%)	28.5% (19.2%; 42.1%)	22.0% (13.7%; 35.1%)
		<b>X/NA</b>	61	70.6% (59.7%; 83.4%)	40.7% (29.6%; 56.0%)	33.4% (22.6%; 49.4%)
	Other and unspecified	<b>All</b>	1,791	80.5% (78.5%; 82.5%)	68.1% (65.6%; 70.6%)	63.3% (60.6%; 66.2%)
		<b>I</b>	803	93.9% (91.9%; 95.9%)	87.7% (84.7%; 90.8%)	83.2% (79.3%; 87.2%)
		<b>II</b>	98	82.4% (74.4%; 91.2%)	64.9% (54.7%; 77.0%)	58.3% (47.2%; 72.1%)
		<b>III</b>	193	76.8% (70.7%; 83.3%)	49.4% (42.3%; 57.7%)	43.6% (36.2%; 52.4%)
		<b>IV</b>	155	39.0% (31.9%; 47.7%)	17.5% (12.3%; 25.1%)	13.0% (8.3%; 20.3%)
		<b>X/NA</b>	543	73.5% (69.7%; 77.5%)	60.5% (56.1%; 65.3%)	56.2% (51.3%; 61.6%)
<b>2013-2017</b>	Endometrioid carcinoma	<b>All</b>	5,081	95.9% (95.2%; 96.6%)	92.4% (91.3%; 93.5%)	91.0% (89.6%; 92.4%)
		<b>I</b>	3,844	100.2% (99.7%; 100.6%)	99.5% (98.5%; 100.5%)	99.5% (98.1%; 100.9%)

Period	type	Stage	Net Survival Probability			
			N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
		<b>II</b>	246	91.9% (87.9%; 96.1%)	84.9% (79.0%; 91.2%)	81.5% (74.1%; 89.6%)
		<b>III</b>	471	85.9% (82.5%; 89.4%)	73.7% (69.1%; 78.5%)	65.4% (60.0%; 71.2%)
		<b>IV</b>	180	57.3% (50.3%; 65.3%)	39.4% (32.5%; 47.8%)	36.1% (29.1%; 44.9%)
		<b>X/NA</b>	340	85.2% (81.0%; 89.7%)	72.1% (66.3%; 78.4%)	66.2% (59.4%; 73.7%)
	Serous carcinoma	<b>All</b>	565	82.6% (79.2%; 86.1%)	58.1% (53.7%; 62.9%)	48.4% (43.8%; 53.6%)
		<b>I</b>	246	97.9% (95.0%; 100.9%)	83.8% (78.1%; 90.1%)	76.2% (69.1%; 84.0%)
		<b>II</b>	33	N<50	N<50	N<50
		<b>III</b>	117	86.7% (80.1%; 93.8%)	45.5% (36.8%; 56.3%)	32.3% (24.1%; 43.4%)
		<b>IV</b>	115	61.2% (52.6%; 71.2%)	26.3% (19.0%; 36.4%)	15.1% (9.3%; 24.3%)
		<b>X/NA</b>	54	45.6% (33.6%; 61.8%)	37.0% (25.0%; 54.6%)	27.0% (16.3%; 44.9%)
	Other and unspecified	<b>All</b>	1,482	79.2% (77.0%; 81.4%)	63.2% (60.5%; 66.1%)	59.0% (55.9%; 62.3%)
		<b>I</b>	734	95.1% (93.2%; 97.1%)	86.5% (83.3%; 89.9%)	82.8% (78.7%; 87.1%)
		<b>II</b>	88	75.1% (66.0%; 85.5%)	64.6% (53.9%; 77.5%)	55.6% (44.0%; 70.2%)
		<b>III</b>	185	75.3% (68.9%; 82.2%)	45.7% (38.4%; 54.4%)	39.6% (32.0%; 49.2%)
		<b>IV</b>	221	43.5% (37.3%; 50.8%)	16.3% (12.0%; 22.3%)	12.9% (8.9%; 18.7%)
		<b>X/NA</b>	256	68.2% (62.3%; 74.7%)	48.6% (42.0%; 56.3%)	45.5% (38.4%; 53.9%)
<b>2018-2022</b>	Endometrioid carcinoma	<b>All</b>	4,957	96.6% (95.9%; 97.3%)	93.5% (92.3%; 94.7%)	92.0% (90.2%; 93.9%)
		<b>I</b>	3,818	100.5% (100.1%; 101.0%)	100.6% (99.5%; 101.6%)	100.7% (98.9%; 102.6%)
		<b>II</b>	245	97.6% (94.6%; 100.7%)	88.9% (82.9%; 95.3%)	87.1% (78.7%; 96.4%)
		<b>III</b>	490	90.6% (87.6%; 93.7%)	79.1% (74.4%; 84.1%)	71.9% (65.1%; 79.4%)
		<b>IV</b>	223	59.4% (53.1%; 66.5%)	38.6% (32.0%; 46.6%)	30.3% (22.6%; 40.7%)
		<b>X/NA</b>	181	74.7% (67.9%; 82.2%)	55.3% (46.7%; 65.5%)	43.7% (33.8%; 56.5%)
	Serous carcinoma	<b>All</b>	675	80.2% (77.0%; 83.6%)	55.2% (50.9%; 59.9%)	46.5% (41.1%; 52.7%)
		<b>I</b>	259	97.9% (95.0%; 100.7%)	81.3% (75.1%; 88.0%)	74.3% (65.4%; 84.5%)

Period	type	Stage	Net Survival Probability			
			N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
		<b>II</b>	45	N<50	N<50	N<50
		<b>III</b>	172	84.0% (78.2%; 90.3%)	50.3% (42.1%; 60.1%)	40.3% (30.6%; 53.1%)
		<b>IV</b>	155	52.1% (44.6%; 60.8%)	25.6% (18.9%; 34.8%)	8.9% (3.8%; 20.9%)
		<b>X/NA</b>	44	N<50	N<50	N<50
	Other and unspecified	<b>All</b>	1,252	74.8% (72.2%; 77.4%)	58.4% (55.2%; 61.8%)	54.7% (50.8%; 58.9%)
		<b>I</b>	586	92.3% (89.8%; 95.0%)	81.6% (77.5%; 86.0%)	77.3% (71.5%; 83.6%)
		<b>II</b>	85	78.0% (68.8%; 88.4%)	60.9% (49.2%; 75.4%)	59.6% (45.8%; 77.4%)
		<b>III</b>	195	73.1% (66.8%; 80.0%)	48.8% (41.3%; 57.8%)	44.0% (35.5%; 54.4%)
		<b>IV</b>	231	39.9% (33.9%; 46.9%)	16.6% (12.0%; 23.0%)	12.1% (7.5%; 19.5%)
		<b>X/NA</b>	155	60.8% (53.1%; 69.6%)	43.3% (35.0%; 53.6%)	42.1% (32.6%; 54.3%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

## 6. CANCER MORTALITY



### 6.1. Corpus uteri cancer mortality: by region

6.1.1. *Corpus uteri cancer mortality\* by region: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2021*

Region	N [CR]																				All ages	ESR2013 (95%CI)
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		
<b>Belgium</b>	0	0	0	0	0	0	0	0	1	0	5	8	13	26	38	55	46	40	22	7	261	4.0
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.0]	[1.3]	[2.0]	[3.5]	[8.0]	[12.8]	[25.8]	[24.9]	[29.6]	[33.2]	[36.4]	[4.5]	(3.5; 4.5)
Brussels	0	0	0	0	0	0	0	0	0	0	1	1	3	0	5	3	0	5	1	0	19	3.8
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.7]	[3.0]	[10.1]	[0.0]	[23.2]	[18.5]	[0.0]	[49.2]	[17.4]	[0.0]	[3.1]	(2.0; 5.5)
Flanders	0	0	0	0	0	0	0	0	1	0	2	4	7	19	23	37	31	25	16	7	172	4.3
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[0.0]	[0.9]	[1.7]	[3.2]	[9.8]	[13.2]	[27.8]	[26.7]	[29.4]	[39.9]	[62.3]	[5.1]	(3.6; 4.9)
Wallonia	0	0	0	0	0	0	0	0	0	0	2	3	3	7	10	15	15	10	5	0	70	3.5
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.6]	[2.4]	[2.5]	[6.4]	[9.9]	[23.5]	[27.2]	[25.0]	[24.5]	[0.0]	[3.8]	(2.6; 4.3)

## 7. CANCER MORTALITY TRENDS



### 7.1. Corpus uteri cancer mortality trends: by region

7.1.1. *Corpus uteri cancer mortality\* trends by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021*

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period
Belgium	<b>N</b>	181	186	181	190	219	200	209	201	188	214	228	209	230	232	237	233	227	261		
	<b>CR</b>	3.4	3.5	3.4	3.5	4.0	3.6	3.8	3.6	3.3	3.8	4.0	3.7	4.0	4.0	4.1	4.0	3.9	4.5		
	<b>ESR2013</b>	3.4	3.4	3.3	3.4	3.9	3.6	3.6	3.4	3.2	3.6	3.7	3.4	3.7	3.7	3.7	3.4	3.5	4.0	0.4 (-0.1; 0.9)	2004-2021
Brussels	<b>N</b>	18	14	14	17	21	11	7	17	17	12	14	15	21	15	14	15	16	19		
	<b>CR</b>	3.5	2.7	2.6	3.2	3.9	2.0	1.2	2.9	2.9	2.0	2.3	2.5	3.5	2.5	2.3	2.4	2.6	3.1		
	<b>ESR2013</b>	3.5	2.8	2.8	3.0	4.0	2.3	1.2	3.4	3.2	2.2	2.9	3.1	4.2	2.8	2.6	2.6	3.4	3.8	0.7 (-2.0; 3.4)	2004-2021
Flanders	<b>N</b>	118	132	129	136	154	141	151	138	130	152	166	143	149	162	163	161	151	172		
	<b>CR</b>	3.9	4.3	4.2	4.4	4.9	4.5	4.8	4.3	4.0	4.7	5.1	4.4	4.5	4.9	4.9	4.8	4.5	5.1		
	<b>ESR2013</b>	3.9	4.3	4.1	4.2	4.7	4.3	4.5	4.0	3.8	4.3	4.4	3.8	3.9	4.2	4.2	3.9	3.8	4.3	-0.3 (-0.8; 0.3)	2004-2021
Wallonia	<b>N</b>	45	40	38	37	44	48	51	46	41	50	48	51	60	55	60	57	60	70		
	<b>CR</b>	2.6	2.3	2.2	2.1	2.5	2.7	2.8	2.5	2.3	2.7	2.6	2.8	3.3	3.0	3.2	3.1	3.2	3.8		
	<b>ESR2013</b>	2.6	2.1	2.2	2.1	2.4	2.7	2.7	2.5	2.1	2.7	2.4	2.7	3.2	2.8	2.9	2.7	3.0	3.5	2.0 (1.0; 2.9)	2004-2021

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

\*Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Departement Zorg; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ)). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2021.

Recommended reference: Cancer Fact Sheets 2022, Belgian Cancer Registry (BCR), 2024